Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $9.39 million. The enterprise value is $6.69 million.
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 10.67 million shares outstanding. The number of shares has increased by 159.16% in one year.
| Current Share Class | 10.67M |
| Shares Outstanding | 10.67M |
| Shares Change (YoY) | +159.16% |
| Shares Change (QoQ) | +5.38% |
| Owned by Insiders (%) | 8.17% |
| Owned by Institutions (%) | 11.01% |
| Float | 8.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| Forward PS | 0.20 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.96
| Current Ratio | 0.96 |
| Quick Ratio | 0.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -50.47 |
Financial Efficiency
Return on equity (ROE) is -531.54% and return on invested capital (ROIC) is -160.61%.
| Return on Equity (ROE) | -531.54% |
| Return on Assets (ROA) | -48.85% |
| Return on Invested Capital (ROIC) | -160.61% |
| Return on Capital Employed (ROCE) | -3,582.64% |
| Revenue Per Employee | $421,376 |
| Profits Per Employee | -$178,409 |
| Employee Count | 93 |
| Asset Turnover | 1.88 |
| Inventory Turnover | 4.03 |
Taxes
In the past 12 months, Biofrontera has paid $20,000 in taxes.
| Income Tax | 20,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.73% in the last 52 weeks. The beta is 0.50, so Biofrontera's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -31.73% |
| 50-Day Moving Average | 0.92 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 50.84 |
| Average Volume (20 Days) | 377,742 |
Short Selling Information
The latest short interest is 187,317, so 1.76% of the outstanding shares have been sold short.
| Short Interest | 187,317 |
| Short Previous Month | 119,900 |
| Short % of Shares Out | 1.76% |
| Short % of Float | 2.21% |
| Short Ratio (days to cover) | 0.61 |
Income Statement
In the last 12 months, Biofrontera had revenue of $39.19 million and -$16.59 million in losses. Loss per share was -$2.10.
| Revenue | 39.19M |
| Gross Profit | 23.13M |
| Operating Income | -16.30M |
| Pretax Income | -23.08M |
| Net Income | -16.59M |
| EBITDA | -16.08M |
| EBIT | -16.30M |
| Loss Per Share | -$2.10 |
Full Income StatementBalance Sheet
The company has $7.25 million in cash and $5.00 million in debt, giving a net cash position of $2.24 million or $0.21 per share.
| Cash & Cash Equivalents | 7.25M |
| Total Debt | 5.00M |
| Net Cash | 2.24M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | -4.67M |
| Book Value Per Share | -0.46 |
| Working Capital | -872,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.39 million and capital expenditures -$5,000, giving a free cash flow of -$9.39 million.
| Operating Cash Flow | -9.39M |
| Capital Expenditures | -5,000 |
| Free Cash Flow | -9.39M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
Gross margin is 59.02%, with operating and profit margins of -41.60% and -42.34%.
| Gross Margin | 59.02% |
| Operating Margin | -41.60% |
| Pretax Margin | -42.29% |
| Profit Margin | -42.34% |
| EBITDA Margin | -41.04% |
| EBIT Margin | -41.60% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -159.16% |
| Shareholder Yield | -159.16% |
| Earnings Yield | -185.70% |
| FCF Yield | -105.12% |
Analyst Forecast
The average price target for Biofrontera is $2.75, which is 212.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.75 |
| Price Target Difference | 212.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 23.82% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biofrontera has an Altman Z-Score of -9.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.44 |
| Piotroski F-Score | 3 |
